Indevus Pharmaceuticals’ Sanctura XR - Last-to-market entrant unlikely to make an impact

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-08-29

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XR’s near-term potential.


Scope

  • Analyzes the commercial potential for IDEV’s Sanctura XR, a recently-approved next-generation OAB agent
  • Datamonitor interviewed twenty-four urologists regarding trends in the treatment of OAB and the potential role of next-generation Sanctura XR


    • Report Highlights
    Based on the data from the Phase II trial, we anticipate that once-daily Sanctura XR will demonstrate a safety and efficacy profile comparable to the original twice-daily Sanctura formulation and support its FDA approval in mid/late 2007.

    Interviewed physicians indicated that all currently marketed OAB products have comparable safety and efficacy profiles and, as the last once-daily OAB option to come to market, if approved, Sanctura XR would not dramatically impact their OAB prescribing habits given the crowded OAB market.


    Reasons to Purchase

  • Understand the commercial potential for Sanctura XR in the treatment of OAB through in-depth analysis based on interviews with leading experts
  • Anticipate likely changes in the future market dynamics for overactive bladder agents given the entry of a new market player

    • Table of Contents

    Other users found this report page using the following search terms: incontinence overactive bladder urge incontinence stress incontinence indevus Sanctura sanctura xr uk cost oab trends market make bladder company

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.